{"cursor":"","markets":[{"can_close_early":true,"close_time":"2027-01-01T04:59:00Z","created_time":"2026-06-17T20:28:39.888017Z","early_close_condition":"This market will close early if the FDA issues a decision on Anitocabtagene Autoleucel (anito-cel) before Jan 1, 2027","event_ticker":"KXANITOCABTAGENE-27","exchange_index":0,"expected_expiration_time":"2027-01-01T15:00:00Z","expiration_time":"2027-01-08T15:00:00Z","expiration_value":"","last_price_dollars":"0.9200","latest_expiration_time":"2027-01-08T15:00:00Z","market_type":"binary","no_ask_dollars":"0.1400","no_bid_dollars":"0.0800","no_sub_title":"a full approval or an accelerated approval","notional_value_dollars":"1.0000","occurrence_datetime":"2027-01-01T15:00:00Z","open_interest_fp":"1304.23","open_time":"2026-06-17T21:30:00Z","previous_price_dollars":"0.9300","previous_yes_ask_dollars":"0.9600","previous_yes_bid_dollars":"0.9000","price_level_structure":"linear_cent","price_ranges":[{"end":"1.0000","start":"0.0000","step":"0.0100"}],"result":"","rules_primary":"If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes.","rules_secondary":"This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. \n\nAnitocabtagene autoleucel (anito-cel) is a personalized, one-time cell therapy made from a patient's own immune cells, reprogrammed in a laboratory to hunt and destroy cancer cells — think of it as taking a soldier from the patient's own army, giving it a custom-made targeting scope, and sending it back in. It is classified as a CAR-T (chimeric antigen receptor T-cell) therapy developed by Arcellx and commercialized in partnership with Gilead Sciences, designed to treat a blood cancer called multiple myeloma. In the trials studied here, it showed very high response rates, with nearly all treated patients responding to the therapy.\n","settlement_bounds_type":"default","settlement_timer_seconds":1800,"status":"active","ticker":"KXANITOCABTAGENE-27-Y","title":"What will the FDA's decision be on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026?","updated_time":"2026-06-17T21:30:00.384562Z","volume_24h_fp":"341.06","volume_fp":"4010.65","yes_ask_dollars":"0.9200","yes_ask_size_fp":"76.00","yes_bid_dollars":"0.8600","yes_bid_size_fp":"77.00","yes_sub_title":"a full approval or an accelerated approval"}]}